South Africa Diabetes Therapeutics Market Analysis

South Africa Diabetes Therapeutics Market Executive Analysis

South African diabetes therapeutics market is expected to grow from $935 Mn in 2022 to $2,145 Mn in 2030 with a CAGR of 10.93% for the forecasted year 2022-30. A recent analysis found that despite the potential to raise money, South Africa's investment in each citizen's health has remained constant for more than ten years. With a GDP of $349.3 Bn, the country has the second-largest economy in Africa, behind Nigeria. However, South Africa does significantly better than its most populous African opponent in terms of GDP per capita. Since 1995–1996, South Africa's healthcare expenditure has increased by 2.5% annually on average. Additionally, from $110 per person, public sector healthcare spending has increased to about $210.

The highest rate of diabetes prevalence in Africa has been recorded in South Africa, at 11.3%. A further 96,000 diabetes-related fatalities are anticipated in the nation in 2021, and diabetes-related healthcare costs have increased to $1,700 per person, amounting to an estimated $7.2 Bn in total.

Exenatide, a glucagon-like peptide-1 (GLP1) receptor agonist based on exendin, is the most recent addition to the range of anti-diabetic medications in South Africa. One of the primary focuses for the creation of novel anti-diabetic medications has been the gastrointestinal hormone (incretin) GLP-1. After eating, the small intestine's L-cells produce GLP-1, which increases pancreatic insulin secretion. Drug-discovery efforts have concentrated on GLP-1 as a therapeutic target since its insulinotropic activity is better preserved in type 2 diabetic patients than that of the incretin, gastric inhibitory polypeptide (glucose-dependent insulinotropic peptide, GIP). In contrast to conventional therapies, GLP-1-based medicines promote insulin secretion in a glucose-dependent manner, resulting in a more normal pattern of insulin secretion with reduced hypoglycemia. GLP-1 agonists demonstrate further potential effects including enhanced endothelial function. Beta-cell mass is either increased or retained in type 1 diabetics and in islet transplant recipients with allograft dysfunction.

Market Dynamics

Market Growth Drivers

The South African government has implemented a sugar tax as a preventative measure. The government is battling obesity and assisting individuals in making better-informed decisions by raising the price of sugary drinks and foods. A Diabetes Prevention Program (DPP) was briefly introduced in South Africa in July 2019. The DPP uses household surveys and meetings for at-risk people to incorporate intervention treatments into a culturally appropriate environment. Through lobbying, funding, and training, the International Diabetes Federation (IDF) collaborates with several organizations in the South African region to lessen the severity of the illness.  Diabetes South Africa (DSA), the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA), and Youth with Diabetes (YWD) are the three organizations that make up the IDF. DSA is a non-profit organization that focuses on enlisting volunteers to push for improved diabetes care, as well as educating the public and advocating for the government for better infrastructure and more affordable healthcare. SEMDSA also investigates the genetic roots and causes of diabetes. Additionally, this group advocates for high treatment standards and broad access to medications. These initiatives are responsible for the growth of the South African diabetes therapeutics market.

Market Restraints

In South Africa, impoverished regions lack access to quality healthcare. It is difficult for residents to get testing or receive treatment if they already have the condition due to a lack of qualified medical personnel and reputable facilities. In South Africa, more than a Mn people do not know if they have diabetes. Diabetes medications can be costly, especially for individuals who need to take insulin. For patients who lack access to proper healthcare coverage or who cannot afford the expense of therapy, this can be a significant barrier. Many diabetic patients have trouble sticking to their treatment plans, which can have an effect on their health outcomes and raise the cost of their care. In low-income and rural areas, where there may be limited access to healthcare and diabetes management education, this is an especially serious concern that can limit the expansion of the South African diabetes therapeutics market.

Competitive Landscape

Key Players

• Clicks Group (ZAF)
• Ascendis Health (ZAF)
• Fend Pharmaceuticals (ZAF)
• Biovac (ZAF)
• iNova Pharmaceuticals (ZAF)
• Eli Lilly
• GlaxoSmithKline
• Johnson Johnson
• Merck
• Novartis
• Novo Nordisk
• Sanofi

Healthcare Policies and Regulatory Landscape

All health goods must be regulated by the South African Health Goods Regulatory Authority, which is responsible for monitoring, assessing, looking into, inspecting, and registering them. This comprises in vitro diagnostics (IVDs), supplemental medications, medical gadgets, and clinical trials. SAHPRA also has the additional duty of managing radiation control in South Africa. Safety, efficacy, and quality are the three pillars on which SAHPRA bases its efforts to guarantee that pharmaceuticals, medical devices, and IVDs adhere to the requirements necessary to safeguard South Africans' health and well-being. These three principles make up the SAHPRA ethos. As part of cooperation law enforcement or cooperative regulatory efforts, the South African Health Items Regulatory Authority (SAHPRA) is permitted to communicate non-public information to the United States Food and Drug Administration (FDA) regarding items under SAHPRA regulation.